The differential role of SSa/SSb and Ro52 antibodies in defining clinical phenotypes in idiopathic inflammatory myopathies
Authors' conclusion
In IIM anti-SSa/SSb or anti-Ro52 positivity is associated with higher ILD rate.
Study context
- Population
- IIM patients >18 years meeting 2017 EULAR/ACR criteria with available anti-SSa/SSb data, Northwell Myositis Center 2007–201860 with anti-Ro52 data
- Participants
- 94 patients
- Exposure
- Anti-SSa/SSb vs anti-SSa/SSb and anti-Ro52 vs anti-Ro52 IIM patients
- Anti-SSa/SSb (+)n = 33
- Anti-Ro52(+)n = 25
- Outcome
- ILD
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Anti-SSa/SSb (+) vs Anti-SSa/SSb negative: P = 0.003 · Anti-Ro52(+) vs Anti-Ro52(-): P = 0,004
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| DLCOAnti-Ro52(+) vs Anti-Ro52(-) | P = 0.003 |
- DLCO: Anti-Ro52(+) 47%
- DLCO: Anti-Ro52(-) 68%
Interstitial lung disease (ILD) severity (pulmonary function tests (PFTs)), anti-SSa/SSb
- Anti-SSa/SSb (+) not associated with increased ILD severity based on PFTs
Other manifestations, anti-SSa/SSb
- Anti-SSa/SSb positivity did not confer a difference in frequency of other manifestations
Venous thromboembolism (VTE) and osteoporosis
- VTE rate, independent of anti-SSa/SSb or anti-Ro52 status
- 10%-12%
- Osteoporosis rate, independent of anti-SSa/SSb or anti-Ro52 status
- 13-17%
Original publication
The differential role of SSa/SSb and Ro52 antibodies in defining clinical phenotypes in idiopathic inflammatory myopathies. Semin Arthritis Rheum. Published 8 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →